Current Advances and Challenges in Mpox Vaccine Development: A Global Landscape Publisher



Shafaati M² ; Mohammadi K^{1, 2, 3} ; Akbarpour S^{1, 4, 5} ; Seifi A² ; Salehi M² Show Affiliations
Source: Therapeutic Advances in Vaccines and Immunotherapy Published:2025

Abstract

Given the surge in mpox outbreaks in 2022 and the advancements in domestic and international vaccine research, the effectiveness of smallpox vaccines in providing cross-protection against mpox remains crucial. Having learned from the COVID-19 pandemic, it is significant to continue evaluating existing vaccines to ensure their safety and efficacy. Developing new vaccines for widespread use against mpox and its emerging strains also serves as a preventive strategy in the ongoing battle against this dynamic infection. Here’s an opportunity to control human-to-human transmission, give short deadlines, and avoid vaccine disparity. Public health systems must take decisive action to prevent the global spread of mpox, particularly among vulnerable groups. This action should include strengthening global surveillance, improving vaccine access, and ensuring equitable distribution, particularly in resource-poor settings, to prevent future outbreaks. This review aims to assess recent advancements and barriers in mpox vaccine development, emphasizing cross-protection and equitable vaccine distribution in resource-poor settings. © The Author(s), 2025.